Clinical Trial Update: An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis [Phase 3]

View source ↗

Summary

Results from an extension Phase 3 study of RPC1063 for moderate-to-severe ulcerative colitis have been completed and posted. The study is sponsored by Celgene.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• RPC1063 (ozanimod)

Snippet

Sponsor: Celgene | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2025-12-31